


Accepted Manuscript

Title: PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges

Author: Hashrul Rashid Ian T Meredith Arthur Nasis

PII: S1443-9506(17)30024-0
DOI: <http://dx.doi.org/doi:10.1016/j.hlc.2016.12.005>
Reference: HLC 2271



To appear in:

Received date: 15-4-2016
Revised date: 2-11-2016
Accepted date: 13-12-2016

Please cite this article as: Rashid H, Meredith IT, Nasis A, PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges, *Heart, Lung and Circulation* (2017), <http://dx.doi.org/10.1016/j.hlc.2016.12.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges

Hashrul Rashid MBBS, Ian T Meredith MBBS, BSc, PhD, FRACP, FCSANZ, Arthur Nasis MBBS, MD, PhD, FRACP, FSCANZ

Monash Cardiovascular Research Centre, MonashHEART, Monash Health and Monash University Department of Medicine (MMC), Melbourne, Vic, Australia

Correspondence:

Dr Arthur Nasis

Head, Acute Cardiac Services,

MonashHeart, Monash Health

246 Clayton Rd, Clayton, 3168, Victoria

Email: arthur.nasis@monashhealth.org

Keywords:

PCSK9 inhibitors, Statins, Lipid lowering therapies

Abbreviations

LDL-C: Low-density lipoprotein cholesterol

LDL-R: Low-density lipoprotein receptor

PCSK9: Proprotein Convertase Subtilisin/Kexin type 9

Download English Version:

<https://daneshyari.com/en/article/5602977>

Download Persian Version:

<https://daneshyari.com/article/5602977>

[Daneshyari.com](https://daneshyari.com)